Not investment advice.Read full disclaimer
Continue with finqOS
Side-by-side valuation, growth, and profitability metrics against the closest competitors.
14-day free trial · No credit card required
52W Range
Volume
Mkt Cap
P/E
Div Yield
Publicly traded Biocon Limited (BIOCON.NS) competitors and peer companies. Compare valuation, revenue growth, margins, and profitability against Laurus Labs Limited, Laurus Labs Limited, Glenmark Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, GlaxoSmithKline Pharmaceuticals Limited, and more.
| Ticker | Company | Market Cap |
|---|---|---|
| LAURUSLABS.NS | Laurus Labs Limited | $808.0B |
| LAURUSLABS.BO | Laurus Labs Limited | $805.5B |
| GLENMARK.BO | Glenmark Pharmaceuticals Limited | $620.7B |
| GLENMARK.NS | Glenmark Pharmaceuticals Limited | $620.2B |
| GLAXO.BO | GlaxoSmithKline Pharmaceuticals Limited | $406.8B |
| GLAXO.NS | GlaxoSmithKline Pharmaceuticals Limited | $405.8B |
| ASTERDM.NS | Aster DM Healthcare Limited | $402.8B |
| PPLPHARMA.NS | Piramal Pharma Limited | $223.7B |
| SYNGENE.BO | SYNGENE.BO | — |
| SYNGENE.NS | SYNGENE.NS | — |